Post partum hair loss treatment is a topic of genuine concern for many new mothers, as the sudden and often dramatic shedding that follows childbirth can be both alarming and distressing. Known clinically as postpartum telogen effluvium, this condition is driven by the sharp fall in oestrogen after delivery, which causes large numbers of hairs to shed simultaneously. The good news is that it is almost always temporary and self-resolving. This article explains why postpartum hair loss happens, when to seek medical advice, which treatments are supported by UK clinical guidance, and how nutrition and lifestyle changes can help support recovery.

Why Postpartum Hair Loss Happens After Pregnancy

Postpartum hair loss occurs because falling oestrogen after delivery causes hairs held in the growth phase during pregnancy to shed simultaneously; follicles remain intact and regrowth is expected within twelve months.

Not sure if this is normal? Chat with one of our pharmacists →

Postpartum hair loss, clinically known as postpartum telogen effluvium, is an extremely common and largely normal physiological response to the hormonal changes that occur after childbirth. During pregnancy, elevated levels of oestrogen prolong the anagen (active growth) phase of the hair cycle, meaning far fewer hairs than usual enter the resting and shedding phase. The result is that many women and people who have given birth enjoy noticeably thicker, fuller hair throughout pregnancy.

Following delivery, oestrogen levels fall sharply and return to pre-pregnancy baselines. This hormonal shift causes a large proportion of hairs that were 'held' in the growth phase to simultaneously enter the telogen (resting) phase and subsequently shed. The shedding is diffuse (spread evenly across the scalp) and non-scarring, which distinguishes it from patchy or scarring forms of hair loss. This process typically begins around two to three months after birth and peaks at approximately three to four months postpartum, though it can continue for up to twelve months in some cases.

It is important to understand that this shedding does not represent permanent hair loss or damage to the hair follicles. The follicles themselves remain intact and healthy. Most people will notice a return to their normal hair density by their baby's first birthday. However, the volume of shedding can be distressing, particularly when combined with the physical and emotional demands of new parenthood. Recognising the underlying mechanism can provide meaningful reassurance during what is often an anxious time.

Sources: NHS (hair loss); British Association of Dermatologists (BAD) patient information on telogen effluvium; Primary Care Dermatology Society (PCDS) guidance on diffuse hair loss.

When to Seek Medical Advice About Hair Loss

Consult a GP if hair loss persists beyond twelve months, is patchy, affects the frontal hairline, or is accompanied by symptoms such as fatigue, weight changes, or scalp abnormalities that may indicate thyroid dysfunction or another underlying condition.

Whilst postpartum telogen effluvium is self-limiting in the vast majority of cases, there are specific circumstances in which it is important to consult a GP or healthcare professional. Understanding these referral triggers helps ensure that any underlying condition is identified and managed promptly.

Seek medical advice if you experience any of the following:

• Hair loss that continues beyond twelve months postpartum without signs of regrowth

• Patchy or asymmetrical hair loss, which may suggest alopecia areata — an autoimmune condition

• Significant thinning at the frontal hairline or temples, which may suggest female pattern hair loss (androgenetic alopecia)

• Signs of hyperandrogenism such as acne, increased facial or body hair, or irregular periods, which may indicate female pattern hair loss or polycystic ovary syndrome (PCOS)

• Hair loss accompanied by fatigue, unexplained weight changes, cold intolerance, or low mood, which could indicate thyroid dysfunction — postpartum thyroiditis is more prevalent in the months following delivery

• Scalp changes such as redness, scaling, itching, pain or tenderness, pustules, or any evidence of scarring, which require prompt dermatological assessment

Your GP may arrange blood tests based on your symptoms and clinical findings. These may include thyroid function tests (TSH and free T4; thyroid peroxidase antibodies if postpartum thyroiditis is suspected), full blood count, ferritin (iron stores), and vitamin B12 and folate levels, as deficiencies in these can exacerbate or independently cause hair shedding. Tests should be clinically indicated rather than requested routinely without supporting symptoms. If you are taking a biotin-containing supplement, inform your GP or the laboratory before blood tests are taken, as high-dose biotin can interfere with certain assays, including thyroid function tests, potentially producing misleading results (MHRA safety advice).

If the diagnosis is unclear, hair loss is severe or atypical, or an underlying dermatological condition is suspected, your GP can refer you to an NHS dermatologist for specialist assessment. Trichologists are hair and scalp specialists who can also provide assessment, but they are not NHS-regulated practitioners and are generally accessed privately rather than through NHS referral.

Sources: NICE CKS: Alopecia — female pattern hair loss; NICE CKS: Alopecia areata; NHS hair loss page; PCDS guidance on diffuse hair loss/telogen effluvium; MHRA safety advice on biotin interference with laboratory tests.

Recommended Treatments for Postpartum Hair Loss in the UK

The primary UK approach is reassurance and watchful waiting; topical minoxidil is licensed for female pattern hair loss but not for postpartum telogen effluvium, and its use during breastfeeding requires specialist guidance.

Because postpartum telogen effluvium is a self-resolving condition, the primary approach in the UK is reassurance and watchful waiting, supported by addressing any identifiable nutritional deficiencies. There is currently no licensed pharmaceutical treatment specifically indicated for postpartum telogen effluvium in the UK.

Topical minoxidil is licensed by the MHRA for female pattern hair loss (androgenetic alopecia) in women. It is available as a Pharmacy (P) medicine — meaning it is sold in pharmacies under pharmacist supervision, not as a general sale item. Licensed products for women include a 2% solution and certain 5% foam preparations (once daily); a pharmacist can advise on the appropriate product. Topical minoxidil is not licensed for postpartum telogen effluvium, and evidence for its use in this context remains limited. Any use for persistent shedding that does not meet the criteria for female pattern hair loss would be off-label and should be discussed with a GP or dermatologist.

Important safety information for minoxidil:

• Minoxidil is contraindicated in pregnancy and should be stopped if you become pregnant or are planning to conceive.

• The Summary of Product Characteristics (SmPC) advises that minoxidil is not recommended during breastfeeding. However, the Specialist Pharmacy Service (SPS/UKDILAS) notes that topical minoxidil may be used with caution whilst breastfeeding if considered necessary, provided direct contact with the infant is avoided and the lowest effective dose is used. Always seek advice from your GP, pharmacist, or a medicines information service before starting minoxidil if you are breastfeeding.

• Common side effects include scalp irritation and unwanted facial hair growth. Systemic absorption is low with topical use but is higher with the 5% formulation.

• Oral minoxidil is unlicensed for hair loss in the UK and should generally be avoided in the postpartum and breastfeeding period unless initiated and supervised by a specialist.

• If you experience a suspected side effect from any medicine, report it to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

For women and people who are not breastfeeding and whose hair loss persists beyond twelve months, a GP or dermatologist may consider:

• Topical minoxidil — on-label if female pattern hair loss is confirmed; off-label for persistent chronic telogen effluvium

• Investigation and treatment of underlying hormonal or nutritional causes

• Referral to an NHS dermatologist for specialist assessment

Many products marketed commercially for postpartum hair loss — including shampoos, serums, and supplements — are not regulated as medicines by the MHRA and lack robust clinical evidence. Whilst some may be safe to use, an appropriately sceptical approach is advised and evidence-based care should be prioritised. Gentle hair care practices — such as avoiding tight hairstyles, excessive heat styling, and harsh chemical treatments — are universally recommended to minimise additional mechanical stress on fragile regrowth hairs.

Sources: MHRA/EMC SmPC for Regaine for Women (2% solution; 5% foam); BNF monograph: Minoxidil (topical); SPS/UKDILAS: Using topical minoxidil during breastfeeding; NICE CKS: Alopecia — female pattern hair loss; PCDS guidance on telogen effluvium.

Nutritional Support and Lifestyle Changes That May Help

Correcting confirmed deficiencies — particularly low ferritin and vitamin D — is the most evidence-based nutritional intervention; supplementation should be guided by blood test results rather than taken routinely.

Nutrition plays a meaningful supporting role in hair health, and addressing any deficiencies identified through blood tests is an important component of postpartum hair loss management. The postpartum period is one of increased nutritional demand, particularly for those who are breastfeeding, making dietary assessment especially relevant.

Key nutrients associated with hair health include:

• Iron (ferritin): Low ferritin is one of the most commonly identified contributors to hair shedding in women. The NHS recommends dietary sources such as red meat, lentils, spinach, and fortified cereals. Supplementation should be guided by blood test results rather than taken routinely without evidence of deficiency.

• Vitamin D: Deficiency is widespread in the UK population. UK Government guidance (based on SACN 2016 recommendations) advises that all adults consider a daily supplement of 10 micrograms (400 IU), particularly during autumn and winter. People who are breastfeeding are advised to take 10 micrograms daily throughout the year. Vitamin D supplements are available free of charge to eligible individuals through the Healthy Start scheme.

• Biotin (Vitamin B7) and other B vitamins: Biotin deficiency is rare but is associated with hair loss. Many postpartum supplements contain B vitamins; however, evidence that supplementation improves hair loss in the absence of confirmed deficiency is limited. Importantly, high-dose biotin supplements can interfere with certain laboratory tests, including thyroid function tests and troponin assays, potentially producing falsely abnormal results. If you are taking a biotin supplement, inform your GP or the laboratory before any blood tests are taken (MHRA safety advice).

• Zinc and protein: Adequate dietary protein is essential for keratin synthesis, the structural protein of hair. Zinc deficiency has been associated with hair shedding; however, high-dose zinc supplementation should be avoided unless deficiency is confirmed, as prolonged high intake can impair copper absorption.

Supplementation is most appropriate when a deficiency has been confirmed by a clinician or blood test. General dietary advice should follow the NHS Eatwell Guide, which provides practical guidance on a balanced diet.

Beyond nutrition, lifestyle factors such as managing stress, prioritising rest where possible, and maintaining gentle physical activity can support overall recovery and wellbeing in the postpartum period. Whilst a link between chronic stress and prolonged telogen effluvium has been proposed, the evidence in the postpartum context specifically is limited. Accepting support from family, health visitors, and community services is encouraged. If low mood or anxiety is contributing to distress about hair loss, speaking with a GP about perinatal mental health support is always appropriate — NICE guideline CG192 (Antenatal and postnatal mental health) supports access to these services.

Sources: NHS: Vitamins, supplements and nutrition in breastfeeding; NHS: Vitamin D; UK Government/SACN (2016) Vitamin D and Health report; MHRA safety advice on biotin interference with laboratory tests; NHS Eatwell Guide; NICE CG192: Antenatal and postnatal mental health.

Frequently Asked Questions